Aviqli (icodec-abae) is the first once-weekly basal insulin approved in the U.S. for adults with type 2 diabetes, replacing seven daily injections with a single weekly dose via a prefilled FlexTouch pen.

Awiqli® is administered once weekly on the same day each week using the FlexTouch pen, with emphasis on correct device use, site rotation, and safety to prevent dosing errors.

The press release provides safety information, contraindications, and reminders to consult healthcare providers for dosing and managing hypoglycemia.

Future steps include post-marketing safety studies in Japan, ongoing type 1 diabetes trials, and potential label changes as new safety data emerge.

Pricing and access: list price is $99 per package, with affordability programs potentially lowering patient costs to about $35 monthly for insured and $55 monthly for uninsured, depending on formulary coverage.

European regulators required educational materials to prevent dosing errors given potential confusion with similar pens.

Novo Nordisk provides Patient Education Center via NovoCare.com offering patient resources and affordability support, plus prescribing information and safety guidelines available at Awiqli.com and in NovoCare resources.

The product is approved only for adults with type 2 diabetes and not for type 1 diabetes or children.

Awiqli is available outside the United States, including the European Union, Canada, Australia, and Japan.

Prescribing information warns against syringe withdrawal, dialing the maximum dose unless prescribed, and mixing with other insulins due to severe overdose risk.

Real-world data and pricing/coverage considerations may affect out-of-pocket costs; a competing weekly insulin (efsitora alfa) could influence future options and pricing.

Dosing transition from daily basal to weekly requires converting the total weekly dose and not self-switching; missed or late doses require monitoring due to longer drug persistence.